Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Glioblastoma Institute
Tumor Boards
Colleague Insights
Living Resources
Conferences
Video Expert Opinion
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Brain Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

featured
Published in Brain Cancer

Expert Opinion / Cases · September 27, 2021

Managing Progressive Diffuse Midline Glioma H3 K27M-Mutant

L. Gonzalez Castro MD, PhD

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

L. Gonzalez Castro MD, PhD

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Dorothy-Myra Sackey

    Sep 28, 2021

    proceed on maintainance temozolomide for the mutation

  • Michela Pisani

    Oct 01, 2021

    Cyberknife rt

  • Isacco Desideri

    Oct 01, 2021

    Maintainance temozolomide plus focal irradation with any high precision radiotherapy technique

  • Tolga Tuncer

    Dec 06, 2021

    Clinical Trial assessment for ONC201 or compassionate use vs SRS

  • Amir Azadi

    Dec 20, 2021

    Clinical Trial assessment for ONC201 or Regorafenib vs. LITT

  • Dec 22, 2024

    Pending Moderator approval.
    Delete

Further Reading

Recently Updated